Hints and tips:
Related Special Reports
...particularly important in the biodefence area and in new emerging diseases, where we don’t know what threats we are going to face,” says Rajeev Venkayya, president of the global vaccine business unit at Takeda...
...This wave of refinancings and several large disposals to cash-rich strategic buyers – such as the $13.7bn sale of Swiss pharmaceutical group Nycomed to Japanese rival Takeda – funnelled back a lot of money...
...Takeda, Nycomed and Nordic Capital, the largest investor with 41 per cent of the shares, all refused to comment....
...Deutsche Bank advised Takeda and Goldman Sachs and Credit Suisse worked for Nycomed....
...Takeda Pharmaceutical is finalising an offer for Nycomed, the specialist privately held Swiss-headquartered generic drugs and consumer healthcare group with a large emerging market presence....
...But deals in Europe have included the second-largest cross-border takeover by a Japanese company, with Takeda Pharmaceutical’s $13.7bn agreement to buy Nycomed of Switzerland....
International Edition